{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:08:24Z","timestamp":1758758904049,"version":"3.44.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"DOI":"10.7759\/cureus.93082","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T07:16:25Z","timestamp":1758698185000},"source":"Crossref","is-referenced-by-count":0,"title":["Leukemias in the Context of Rheumatoid Arthritis: Shared Pathways and Clinical Perspectives"],"prefix":"10.7759","author":[{"given":"Alaa","family":"Osman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nipun","family":"Addla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashesh","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badriya","family":"Ali\u00a0Alansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Aldhuaina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakriti","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandhu Anil","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Rheumatoid arthritis","author":"Amaya-Amaya J","year":"2013","unstructured":"Amaya-Amaya J, Rojas-Villarraga A, Mantilla RD, Anaya JM. Rheumatoid arthritis. Autoimmunity: From Bench to Bedside. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, Anaya JM (ed): El Rosario University Press, Bogota, Colombia; 2013."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo Q","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018, 6:15. 10.1038\/s41413-018-0016-9","journal-title":"Bone Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.2.132","article-title":"Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases","volume":"43","author":"Symmons DP","year":"1984","unstructured":"Symmons DP, Ahern M, Bacon PA, et al.. Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. Ann Rheum Dis. 1984, 43:132-5. 10.1136\/ard.43.2.132","journal-title":"Ann Rheum Dis"},{"key":"ref4","article-title":"Acute leukemia in rheumatoid arthritis treated with cytotoxic agents","volume":"3","author":"Seidenfeld AM","year":"1976","unstructured":"Seidenfeld AM, Smythe HA, Ogryzlo MA, Urowitz MB, Dotten DA. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol. 1976, 3:295-304.","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9298-y","article-title":"Risk of cancer among rheumatoid arthritis patients in California","volume":"20","author":"Parikh-Patel A","year":"2009","unstructured":"Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009, 20:1001-10. 10.1007\/s10552-009-9298-y","journal-title":"Cancer Causes Control"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8631061","article-title":"Autoimmune\/Inflammatory arthritis associated lymphomas: who is at risk?","volume":"2016","author":"Yadlapati S","year":"2016","unstructured":"Yadlapati S, Efthimiou P. Autoimmune\/Inflammatory arthritis associated lymphomas: who is at risk?. Biomed Res Int. 2016, 2016:8631061. 10.1155\/2016\/8631061","journal-title":"Biomed Res Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113017","article-title":"Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies","volume":"10","author":"Mueller AL","year":"2021","unstructured":"Mueller AL, Payandeh Z, Mohammadkhani N, et al.. Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells. 2021, 10:3017. 10.3390\/cells10113017","journal-title":"Cells"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.03.004","article-title":"Innate immunity and rheumatoid arthritis","volume":"36","author":"Gierut A","year":"2010","unstructured":"Gierut A, Perlman H, Pope RM. Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am. 2010, 36:271-96. 10.1016\/j.rdc.2010.03.004","journal-title":"Rheum Dis Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"van Delft MA","year":"2020","unstructured":"van Delft MA, Huizinga TW. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020, 110:102392. 10.1016\/j.jaut.2019.102392","journal-title":"J Autoimmun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang S","year":"2022","unstructured":"Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci. 2022, 23:905. 10.3390\/ijms23020905","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effector cytokines in inflammation","volume":"28","author":"Ouyang W","year":"2008","unstructured":"Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008, 28:454-67. 10.1016\/j.immuni.2008.03.004","journal-title":"Immunity"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo N","year":"2021","unstructured":"Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021, 22:10922. 10.3390\/ijms222010922","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/561459","article-title":"The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis","volume":"2014","author":"Wojdasiewicz P","year":"2014","unstructured":"Wojdasiewicz P, Poniatowski \u0141A, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014, 2014:561459. 10.1155\/2014\/561459","journal-title":"Mediators Inflamm"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051127","article-title":"Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice","volume":"9","author":"Wysocki T","year":"2020","unstructured":"Wysocki T, Olesi\u0144ska M, Paradowska-Gorycka A. Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice. Cells. 2020, 9:1127. 10.3390\/cells9051127","journal-title":"Cells"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane KD","year":"2017","unstructured":"Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017, 31:3-18. 10.1016\/j.berh.2017.08.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.53.3-4.289","article-title":"Environmental epigenetics and its implication on disease risk and health outcomes","volume":"53","author":"Ho SM","year":"2012","unstructured":"Ho SM, Johnson A, Tarapore P, Janakiram V, Zhang X, Leung YK. Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J. 2012, 53:289-305. 10.1093\/ilar.53.3-4.289","journal-title":"ILAR J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.904292","article-title":"Disease burden, risk factors, and trends of leukaemia: a global analysis","volume":"12","author":"Huang J","year":"2022","unstructured":"Huang J, Chan SC, Ngai CH, et al.. Disease burden, risk factors, and trends of leukaemia: a global analysis. Front Oncol. 2022, 12:904292. 10.3389\/fonc.2022.904292","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036152","article-title":"Chronic lymphocytic leukemia and autoimmunity: a systematic review","volume":"96","author":"Hodgson K","year":"2011","unstructured":"Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011, 96:752-61. 10.3324\/haematol.2010.036152","journal-title":"Haematologica"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231183330","article-title":"Immune dysregulation and potential targeted therapy in myelodysplastic syndrome","volume":"14","author":"Zhang X","year":"2023","unstructured":"Zhang X, Yang X, Ma L, Zhang Y, Wei J. Immune dysregulation and potential targeted therapy in myelodysplastic syndrome. Ther Adv Hematol. 2023, 14:10.1177\/20406207231183330","journal-title":"Ther Adv Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772408","article-title":"Inflammatory cytokines shape an altered immune response during myeloid malignancies","volume":"12","author":"Camacho V","year":"2021","unstructured":"Camacho V, Kuznetsova V, Welner RS. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. 2021, 12:772408. 10.3389\/fimmu.2021.772408","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga F","year":"2020","unstructured":"Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020, 21:1625. 10.3390\/ijms21051825","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi F","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015, 126:573-81. 10.1182\/blood-2015-03-567388","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143557","article-title":"NF-\u03baB: A druggable target in acute myeloid leukemia","volume":"14","author":"Di Francesco B","year":"2022","unstructured":"Di Francesco B, Verzella D, Capece D, et al.. NF-\u03baB: A druggable target in acute myeloid leukemia. Cancers (Basel). 2022, 14:3557. 10.3390\/cancers14143557","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8907","article-title":"Targeting the interleukin-6\/Jak\/stat pathway in human malignancies","volume":"30","author":"Sansone P","year":"2012","unstructured":"Sansone P, Bromberg J. Targeting the interleukin-6\/Jak\/stat pathway in human malignancies. J Clin Oncol. 2012, 30:1005-14. 10.1200\/JCO.2010.31.8907","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e6","article-title":"IL-17 producing cells in tumor immunity: friends or foes?","volume":"20","author":"Kuen DS","year":"2020","unstructured":"Kuen DS, Kim BS, Chung Y. IL-17 producing cells in tumor immunity: friends or foes?. Immune Netw. 2020, 20:e6. 10.4110\/in.2020.20.e6","journal-title":"Immune Netw"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44270-3","article-title":"Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia","volume":"15","author":"Wang F","year":"2024","unstructured":"Wang F, Li Y, Yang Z, et al.. Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Nat Commun. 2024, 15:203. 10.1038\/s41467-023-44270-3","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0057","article-title":"IL-17, IL-21, and IL-22 cytokines of T helper 17 cells in cancer","volume":"39","author":"Nalbant A","year":"2019","unstructured":"Nalbant A. IL-17, IL-21, and IL-22 cytokines of T helper 17 cells in cancer. J Interferon Cytokine Res. 2019, 39:56-60. 10.1089\/jir.2018.0057","journal-title":"J Interferon Cytokine Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071307","article-title":"Large granular lymphocytic leukemia: clinical features, molecular pathogenesis, diagnosis and treatment","volume":"16","author":"Ullah F","year":"2024","unstructured":"Ullah F, Markouli M, Orland M, Ogbue O, Dima D, Omar N, Mustafa Ali MK. Large granular lymphocytic leukemia: clinical features, molecular pathogenesis, diagnosis and treatment. Cancers (Basel). 2024, 16:1307. 10.3390\/cancers16071307","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00422-1","article-title":"Role of innate immunological\/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review","volume":"12","author":"Vegivinti CT","year":"2023","unstructured":"Vegivinti CT, Keesari PR, Veeraballi S, et al.. Role of innate immunological\/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. Exp Hematol Oncol. 2023, 12:60. 10.1186\/s40164-023-00422-1","journal-title":"Exp Hematol Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70152","article-title":"Immune-dysregulation harnessing in myeloid neoplasms","volume":"13","author":"Sharifi MJ","year":"2024","unstructured":"Sharifi MJ, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M. Immune-dysregulation harnessing in myeloid neoplasms. Cancer Med. 2024, 13:e70152. 10.1002\/cam4.70152","journal-title":"Cancer Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/art.40654","article-title":"Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: a comprehensive analysis of 529 patients","volume":"70","author":"Schwaneck EC","year":"2018","unstructured":"Schwaneck EC, Renner R, Junker L, et al.. Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: a comprehensive analysis of 529 patients. Arthritis Rheumatol. 2018, 70:1914-22. 10.1002\/art.40654","journal-title":"Arthritis Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.181","article-title":"Chronic neutropenia in LGL leukemia and rheumatoid arthritis","volume":"2017","author":"Gazitt T","year":"2017","unstructured":"Gazitt T, Loughran TP Jr. Chronic neutropenia in LGL leukemia and rheumatoid arthritis. Hematology Am Soc Hematol Educ Program. 2017, 2017:181-6. 10.1182\/asheducation-2017.1.181","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04757-4","article-title":"Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis","volume":"41","author":"Gorodetskiy VR","year":"2021","unstructured":"Gorodetskiy VR, Sidorova YV, Kupryshina NA, Vasilyev VI, Probatova NA, Ryzhikova NV, Sudarikov AB. Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatol Int. 2021, 41:147-56. 10.1007\/s00296-020-04757-4","journal-title":"Rheumatol Int"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620966863","article-title":"Chronic myelomonocytic leukemia presenting with polyserositis and seropositivity for rheumatoid arthritis","volume":"8","author":"Kunnumpurath A","year":"2020","unstructured":"Kunnumpurath A, Desikan SP, McClain C, Desikan R. Chronic myelomonocytic leukemia presenting with polyserositis and seropositivity for rheumatoid arthritis. J Investig Med High Impact Case Rep. 2020, 8:10.1177\/2324709620966863","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00852-7","article-title":"Exploring the relationship between immune heterogeneity characteristic genes of rheumatoid arthritis and acute myeloid leukemia","volume":"15","author":"Jiang C","year":"2024","unstructured":"Jiang C, Jiang W, Liu P, Sun W, Teng W. Exploring the relationship between immune heterogeneity characteristic genes of rheumatoid arthritis and acute myeloid leukemia. Discov Oncol. 2024, 15:1. 10.1007\/s12672-023-00852-7","journal-title":"Discov Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00977-0","article-title":"The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders","volume":"14","author":"Semenzato G","year":"2024","unstructured":"Semenzato G, Calabretto G, Teramo A, Gasparini VR, Rampazzo E, Baril\u00e0 G, Zambello R. The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders. Blood Cancer J. 2024, 14:13. 10.1038\/s41408-024-00977-0","journal-title":"Blood Cancer J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.869205","article-title":"Intersection between large granular lymphocyte leukemia and rheumatoid arthritis","volume":"12","author":"Moosic KB","year":"2022","unstructured":"Moosic KB, Ananth K, Andrade F, Feith DJ, Darrah E, Loughran TP Jr. Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front Oncol. 2022, 12:869205. 10.3389\/fonc.2022.869205","journal-title":"Front Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2022.07.004","article-title":"The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome","volume":"59","author":"Savola P","year":"2022","unstructured":"Savola P, Bhattacharya D, Huuhtanen J. The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome. Semin Hematol. 2022, 59:123-30. 10.1053\/j.seminhematol.2022.07.004","journal-title":"Semin Hematol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.06.006","article-title":"Autoimmune manifestations in large granular lymphocyte leukemia","volume":"12","author":"Bockorny B","year":"2012","unstructured":"Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk. 2012, 12:400-5. 10.1016\/j.clml.2012.06.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.03.515","article-title":"T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia","volume":"132","author":"Shah A","year":"2009","unstructured":"Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009, 132:145-52. 10.1016\/j.clim.2009.03.515","journal-title":"Clin Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05396-7","article-title":"The risk of leukemia in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"40","author":"Luo X","year":"2021","unstructured":"Luo X, He Y, Xu W, et al.. The risk of leukemia in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2021, 40:1283-9. 10.1007\/s10067-020-05396-7","journal-title":"Clin Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon M","year":"2023","unstructured":"Beydon M, Pinto S, De Rycke Y, Fautrel B, Mariette X, Seror R, Tubach F. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. Lancet Reg Health Eur. 2023, 35:100768. 10.1016\/j.lanepe.2023.100768","journal-title":"Lancet Reg Health Eur"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon TA","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015, 17:212. 10.1186\/s13075-015-0728-9","journal-title":"Arthritis Res Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0064-4","article-title":"Malignancy incidence, management, and prevention in patients with rheumatoid arthritis","volume":"4","author":"Wilton KM","year":"2017","unstructured":"Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017, 4:333-47. 10.1007\/s40744-017-0064-4","journal-title":"Rheumatol Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2972-4","article-title":"The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study","volume":"34","author":"Lin YC","year":"2015","unstructured":"Lin YC, Chou HW, Tsai WC, Yen JH, Chang SJ, Lin YC. The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study. Clin Rheumatol. 2015, 34:1195-202. 10.1007\/s10067-015-2972-4","journal-title":"Clin Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken130","article-title":"Cancer risk in hospitalized rheumatoid arthritis patients","volume":"47","author":"Hemminki K","year":"2008","unstructured":"Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford). 2008, 47:698-701. 10.1093\/rheumatology\/ken130","journal-title":"Rheumatology (Oxford)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.006","article-title":"Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population","volume":"37","author":"Ab\u00e1solo L","year":"2008","unstructured":"Ab\u00e1solo L, J\u00fadez E, Descalzo MA, Gonz\u00e1lez-Alvaro I, Jover JA, Carmona L. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum. 2008, 37:388-97. 10.1016\/j.semarthrit.2007.08.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.09.006","article-title":"Malignancy risks with biologic therapies","volume":"38","author":"Cush JJ","year":"2012","unstructured":"Cush JJ, Dao KH. Malignancy risks with biologic therapies. Rheum Dis Clin North Am. 2012, 38:761-70. 10.1016\/j.rdc.2012.09.006","journal-title":"Rheum Dis Clin North Am"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano T","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021, 33:127-48. 10.1093\/intimm\/dxaa078","journal-title":"Int Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.03.017","article-title":"Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging","volume":"28","author":"Young K","year":"2021","unstructured":"Young K, Eudy E, Bell R, et al.. Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging. Cell Stem Cell. 2021, 28:1473-82.e7. 10.1016\/j.stem.2021.03.017","journal-title":"Cell Stem Cell"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.931493","article-title":"Epigenetic regulation of inflammatory signaling and inflammation-induced cancer","volume":"10","author":"Tan SY","year":"2022","unstructured":"Tan SY, Zhang J, Tee WW. Epigenetic regulation of inflammatory signaling and inflammation-induced cancer. Front Cell Dev Biol. 2022, 10:931493. 10.3389\/fcell.2022.931493","journal-title":"Front Cell Dev Biol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2174\/138920207783591690","article-title":"The HLA region and autoimmune disease: associations and mechanisms of action","volume":"8","author":"Gough SC","year":"2007","unstructured":"Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007, 8:453-65. 10.2174\/138920207783591690","journal-title":"Curr Genomics"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1086\/675979","article-title":"Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series)","volume":"4","author":"Loscalzo J","year":"2014","unstructured":"Loscalzo J, Handy DE. Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series). Pulm Circ. 2014, 4:169-74. 10.1086\/675979","journal-title":"Pulm Circ"},{"key":"ref55","article-title":"B lymphocytes in autoimmunity","author":"Izquierdo JH","year":"2013","unstructured":"Izquierdo JH, Ca\u00f1as CA, Tob\u00f3n GJ. B lymphocytes in autoimmunity. Autoimmunity: From Bench to Bedside. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al. (ed): El Rosario University Press, Bogota, Colombia; 2013."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512222","article-title":"Dysregulated signalling pathways driving anticancer drug resistance","volume":"24","author":"Bou Antoun N","year":"2023","unstructured":"Bou Antoun N, Chioni AM. Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci. 2023, 24:12222. 10.3390\/ijms241512222","journal-title":"Int J Mol Sci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.679929","article-title":"Recent developments on immunotherapy for brain cancer","volume":"17","author":"Wainwright DA","year":"2012","unstructured":"Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS. Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs. 2012, 17:181-202. 10.1517\/14728214.2012.679929","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon DH","year":"2014","unstructured":"Solomon DH, Kremer JM, Fisher M, et al.. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014, 43:489-97. 10.1016\/j.semarthrit.2013.08.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard L","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, et al.. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022, 12:7140. 10.1038\/s41598-022-10777-w","journal-title":"Sci Rep"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2023.07.004","article-title":"Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis","volume":"19","author":"Balsa A","year":"2023","unstructured":"Balsa A, D\u00edaz Del Campo Fontecha P, Silva Fern\u00e1ndez L, et al.. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed). 2023, 19:533-48. 10.1016\/j.reumae.2023.07.004","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: not just another kinase","volume":"21","author":"Agashe RP","year":"2022","unstructured":"Agashe RP, Lippman SM, Kurzrock R. JAK: not just another kinase. Mol Cancer Ther. 2022, 21:1757-64. 10.1158\/1535-7163.MCT-22-0323","journal-title":"Mol Cancer Ther"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0449-5","article-title":"The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study","volume":"16","author":"Wu CY","year":"2014","unstructured":"Wu CY, Chen DY, Shen JL, et al.. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther. 2014, 16:449. 10.1186\/s13075-014-0449-5","journal-title":"Arthritis Res Ther"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling J","year":"2005","unstructured":"Askling J, Fored CM, Baecklund E, et al.. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64:1414-20. 10.1136\/ard.2004.033241","journal-title":"Ann Rheum Dis"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2020-0001","article-title":"Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: a single-center experience","volume":"1","author":"Cometi L","year":"2020","unstructured":"Cometi L, Bruni C, Passavanti S, et al.. Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: a single-center experience. Rheumatol Immunol Res. 2020, 1:39-45. 10.2478\/rir-2020-0001","journal-title":"Rheumatol Immunol Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al.. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021, 73:924-39. 10.1002\/acr.24596","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.041","article-title":"Diagnostic testing and interpretation of tests for autoimmunity","volume":"125","author":"Castro C","year":"2010","unstructured":"Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol. 2010, 125:S238-47. 10.1016\/j.jaci.2009.09.041","journal-title":"J Allergy Clin Immunol"},{"key":"ref67","article-title":"Conventional Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis","author":"Hill S","year":"2021","unstructured":"Hill S, Frey N. Conventional Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON); 2021."},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony S","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023, 98:502-26. 10.1002\/ajh.26822","journal-title":"Am J Hematol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133512","article-title":"Modern risk stratification of acute myeloid leukemia in 2023: integrating established and emerging prognostic factors","volume":"15","author":"Boscaro E","year":"2023","unstructured":"Boscaro E, Urbino I, Catania FM, et al.. Modern risk stratification of acute myeloid leukemia in 2023: integrating established and emerging prognostic factors. Cancers (Basel). 2023, 15:3512. 10.3390\/cancers15133512","journal-title":"Cancers (Basel)"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1036239","article-title":"Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma","volume":"13","author":"Li H","year":"2022","unstructured":"Li H, Yu L, Zhang X, Shang J, Duan X. Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma. Front Immunol. 2022, 13:1036239. 10.3389\/fimmu.2022.1036239","journal-title":"Front Immunol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1182\/hem.v16.4.9711","article-title":"Autoimmune disorders and the development of myeloid disease: should we always blame the therapy?","volume":"16","author":"Zeidan A","year":"2019","unstructured":"Zeidan A, Boddu P. Autoimmune disorders and the development of myeloid disease: should we always blame the therapy?. Hematol. 2019, 16:10.1182\/hem.v16.4.9711","journal-title":"Hematol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2016.03.001","article-title":"Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link","volume":"30","author":"Egiziano G","year":"2016","unstructured":"Egiziano G, Bernatsky S, Shah AA. Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol. 2016, 30:53-62. 10.1016\/j.berh.2016.03.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/3188216","article-title":"Identification and verification of novel biomarkers involving rheumatoid arthritis with multimachine learning algorithms: an in silico and in vivo study","volume":"2024","author":"Liu F","year":"2024","unstructured":"Liu F, Ye J, Wang S, et al.. Identification and verification of novel biomarkers involving rheumatoid arthritis with multimachine learning algorithms: an in silico and in vivo study. Mediators Inflamm. 2024, 2024:3188216. 10.1155\/2024\/3188216","journal-title":"Mediators Inflamm"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686155","article-title":"Promising therapeutic targets for treatment of rheumatoid arthritis","volume":"12","author":"Huang J","year":"2021","unstructured":"Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising therapeutic targets for treatment of rheumatoid arthritis. Front Immunol. 2021, 12:686155. 10.3389\/fimmu.2021.686155","journal-title":"Front Immunol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0623-3","article-title":"Future therapeutic targets in rheumatoid arthritis?","volume":"39","author":"Cheung TT","year":"2017","unstructured":"Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis?. Semin Immunopathol. 2017, 39:487-500. 10.1007\/s00281-017-0623-3","journal-title":"Semin Immunopathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/401463-leukemias-in-the-context-of-rheumatoid-arthritis-shared-pathways-and-clinical-perspectives","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T07:16:26Z","timestamp":1758698186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/401463-leukemias-in-the-context-of-rheumatoid-arthritis-shared-pathways-and-clinical-perspectives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":75,"URL":"https:\/\/doi.org\/10.7759\/cureus.93082","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}